MedPath

OphtAI Diagnostic Performance Validation for Automated Screening of Eye Diseases

Not Applicable
Recruiting
Conditions
Age-related Maculopathy
Diabetic Retinopathy
Age-Related Macular Degeneration
Diabetic Macular Edema
Glaucoma
Interventions
Device: Eye Fundus Double Capture for Eye Diseases Screening with OphtAI Medical Device
Registration Number
NCT05752045
Lead Sponsor
Evolucare Technologies
Brief Summary

Evolucare OphtAI is a medical device offering automated, artificial intelligence powered, screening capabilities for Diabetic Retinopathy, Diabetic Macular Edema, Glaucoma, ARM and AMD, whose performances will by tested through the OphtAI-EVAL.

Detailed Description

OphtAI-Eval: is a prospective, multicentre, post-marketing clinical follow-up study (SCAC) of diagnostic validation (comparative vs gold standard).

It aims to: validate the diagnostic performance of the OphtAI software for the automated screening of diabetic retinopathy, diabetic macular edema, glaucoma, ARM and AMD.

Evolucare OphtAI is a medical imaging console for ophthalmology, interfaced with Evolucare Imaging.

It allows the detection, by statistical learning algorithms, of the following ocular pathologies using photographs of the retina:

* Diabetic retinopathy (DR) (including gradation),

* Diabetic macular edema (DME)

* Age-related macular degeneration (AMD)

* Age-related maculopathy (ARM, early form of AMD),

* Glaucoma.

Evolucare OphtAI, is available on the French market since March 2019.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
1389
Inclusion Criteria

The characteristics required for a subject to take part in the research are

  • Male or female over 18,
  • Type 1 or 2 diabetic,
  • Presenting for screening for diabetic retinopathy,
  • Beneficiary of a social security scheme,
  • For whom written consent has been obtained for participation in the protocol.
Exclusion Criteria

The following characteristics do not allow the subject to take part in the research:

  • Patient with known DR, more severe than "minimal", including having been treated,
  • Any other condition that, in the opinion of the health professionals, may interfere with their ability to complete the study or may present a significant risk,
  • Presence of social, medical and/or psychological factors that may compromise the patient's adherence to the protocol,
  • Simultaneously participating in another clinical research protocol or having recently participated in another research study for which the exclusion period would not be completed.

Patients who participate in this research will not be able to participate in another research at the same time. However, there is no exclusion period at the end of this research for participation in any other study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Diabetic patient group assessed for multiple eye diseasesEye Fundus Double Capture for Eye Diseases Screening with OphtAI Medical DeviceEach patient eye disease status will be assessed by expert readers so to provide ground truth against which algorithms performances will be assessed
Primary Outcome Measures
NameTimeMethod
Referable Diabetic Retinopathy screening sensitivity/specificity1 year

Referable Diabetic Retinopathy screening sensitivity/specificity evaluation (OphtAI software vs Expert reader) for RDR-EOphtha and RDR-OphDiaT_full algorithms

Secondary Outcome Measures
NameTimeMethod
Diabetic retinopathy grading + RDR-OphDiaT_full +DME algorithms combination sensitivity/specificity for RDR detection1 year

Referable Diabetic Retinopathy screening sensitivity/specificity evaluation (OphtAI software vs Expert reader) for RDR-OphDiaT_full , RD grading and DME algorithms combination

Diabetic retinopathy grading + RDR-OphDiaT_full algorithms combination sensitivity/specificity for RDR detection1 year

Referable Diabetic Retinopathy screening sensitivity/specificity evaluation (OphtAI software vs Expert reader) for RDR-OphDiaT_full and RD grading algorithms combination

Diabetic retinopathy grading + RDR-EOphtha +DME algorithms combination sensitivity/specificity for RDR detection1 year

Referable Diabetic Retinopathy screening sensitivity/specificity evaluation (OphtAI software vs Expert reader) for RDR-EOphtha, RD grading and DME algorithms combination

Diabetic Macular Edema algorithm sensitivity/specificityfor DME detection1 year

Diabetic Macular Edema screening sensitivity/specificity evaluation (OphtAI software vs Expert reader) for DME algorithm

Glaucoma algorithms sensitivity/specificity for Glaucoma suspicion1 year

Glaucoma screening sensitivity/specificity evaluation (OphtAI software vs Expert reader) for Glaucoma algorithms

Diabetic retinopathy grading sensitivity/specificity1 year

Diabetic retinopathy grading performance (OphtAI software vs Expert reader) for each grading sub algorithms (sensitivity/specificity) and globally (accuracy/agreement ratio)

Age-Related Macular Degeneration algorithm sensitivity/specificity for AMD detection1 year

AMD screening sensitivity/specificity evaluation (OphtAI software vs Expert reader) for AMD algorithm, for all forms and for either atrophic or neovascular AMD

Diabetic retinopathy grading + RDR-EOphtha algorithms combination sensitivity/specificity for RDR detection1 year

Referable Diabetic Retinopathy screening sensitivity/specificity evaluation (OphtAI software vs Expert reader) for RDR-EOphtha and RD grading algorithms combination

Quality algorithm accuracy for quality assessment1 year

Bad quality images sensitivity/specificity evaluation (OphtAI software vs Expert reader) for quality assessment algorithms

Age-Related Maculopathy algorithm ("drusen") sensitivity/specificity for ARM detection1 year

ARM screening sensitivity/specificity evaluation (OphtAI software vs Expert reader) for ARM algorithm, for all forms and for either macular or peripheric drusen, or for either hard/soft drusen

Laterality determination algorithm accuracy for laterality assessment1 year

Laterality accuracy of OphtAI software vs Expert reader for laterality determination algorithm

Trial Locations

Locations (12)

Clinique Honoré Cave

🇫🇷

Montauban, France

OPHDIAT

🇫🇷

Paris, Île De France, France

CHU Brest

🇫🇷

Brest, France

Centre Aix Vision

🇫🇷

Aix-en-Provence, France

Centre d'examens de santé de la CPAM 93

🇫🇷

Corbeil-Essonnes, France

Centre Ophtalmologique Brétigny Essonne

🇫🇷

Brétigny-sur-Orge, France

CH SUD Francilien Corbeil Essonne

🇫🇷

Corbeil Essonnes, France

Retinodiab Bourgogne

🇫🇷

Dijon, France

CHU Nantes

🇫🇷

Nantes, France

Retinodiab Franche-Comté

🇫🇷

Roppe, France

Diabète Occitanie

🇫🇷

Toulouse, France

CHU Toulouse

🇫🇷

Toulouse, France

© Copyright 2025. All Rights Reserved by MedPath